| Genomic hallmarks of localized, non-indolent prostate cancer M Fraser, VY Sabelnykova, TN Yamaguchi, LE Heisler, J Livingstone, ... Nature 541 (7637), 359-364, 2017 | 633 | 2017 |
| Spatial genomic heterogeneity within localized, multifocal prostate cancer PC Boutros, M Fraser, NJ Harding, R De Borja, D Trudel, E Lalonde, ... Nature genetics 47 (7), 736-745, 2015 | 551 | 2015 |
| Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study E Lalonde, AS Ishkanian, J Sykes, M Fraser, H Ross-Adams, N Erho, ... The lancet oncology 15 (13), 1521-1532, 2014 | 396 | 2014 |
| An integrated multidisciplinary algorithm for the management of spinal metastases: an International Spine Oncology Consortium report DE Spratt, WH Beeler, FY de Moraes, LD Rhines, JJ Gemmete, ... The Lancet Oncology 18 (12), e720-e730, 2017 | 303 | 2017 |
| Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression S Chen, G Zhu, Y Yang, F Wang, YT Xiao, N Zhang, X Bian, Y Zhu, Y Yu, ... Nature cell biology 23 (1), 87-98, 2021 | 300 | 2021 |
| ONECUT2 is a driver of neuroendocrine prostate cancer H Guo, X Ci, M Ahmed, JT Hua, F Soares, D Lin, L Puca, A Vosoughi, ... Nature communications 10 (1), 278, 2019 | 221 | 2019 |
| A prostate cancer “nimbosus”: genomic instability and SChLAP1 dysregulation underpin aggression of intraductal and cribriform subpathologies MLK Chua, W Lo, M Pintilie, J Murgic, E Lalonde, V Bhandari, ... European urology 72 (5), 665-674, 2017 | 183 | 2017 |
| Clinical integration of machine learning for curative-intent radiation treatment of patients with prostate cancer C McIntosh, L Conroy, MC Tjong, T Craig, A Bayley, C Catton, ... Nature medicine 27 (6), 999-1005, 2021 | 154 | 2021 |
| A systematic review of the evidence for the decipher genomic classifier in prostate cancer NK Jairath, A Dal Pra, R Vince Jr, RT Dess, WC Jackson, JJ Tosoian, ... European urology 79 (3), 374-383, 2021 | 152 | 2021 |
| Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials MP Deek, K Van der Eecken, P Sutera, RA Deek, V Fonteyne, AA Mendes, ... Journal of clinical oncology 40 (29), 3377-3382, 2022 | 147 | 2022 |
| Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer M Fraser, A Berlin, RG Bristow, T Van der Kwast Urologic Oncology: Seminars and Original Investigations 33 (2), 85-94, 2015 | 139 | 2015 |
| Prognostic role of Ki-67 score in localized prostate cancer: a systematic review and meta-analysis A Berlin, JF Castro-Mesta, L Rodriguez-Romo, D Hernandez-Barajas, ... Urologic Oncology: Seminars and Original Investigations 35 (8), 499-506, 2017 | 108 | 2017 |
| Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis AR Zlotta, LK Ballas, A Niemierko, K Lajkosz, C Kuk, G Miranda, ... The lancet oncology 24 (6), 669-681, 2023 | 107 | 2023 |
| Implementation and outcomes of virtual care across a tertiary cancer center during COVID-19 A Berlin, M Lovas, T Truong, S Melwani, J Liu, ZA Liu, A Badzynski, ... JAMA oncology 7 (4), 597-602, 2021 | 93 | 2021 |
| Stereotactic ablative radiotherapy for the management of spinal metastases: a review RM Glicksman, MC Tjong, WFP Neves-Junior, DE Spratt, KLM Chua, ... JAMA oncology 6 (4), 567-577, 2020 | 92 | 2020 |
| The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited MP Deek, K Van der Eecken, R Phillips, NR Parikh, PI Velho, TL Lotan, ... European urology 80 (5), 632-640, 2021 | 89 | 2021 |
| Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial NM Richard, LJ Bernstein, WP Mason, N Laperriere, C Maurice, BA Millar, ... Journal of neuro-oncology 142, 565-575, 2019 | 83 | 2019 |
| Low-grade prostate cancer: time to stop calling it cancer SE Eggener, A Berlin, AJ Vickers, GP Paner, H Wolinsky, MR Cooperberg Journal of Clinical Oncology 40 (27), 3110-3114, 2022 | 77 | 2022 |
| Curative-intent metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer: a prospective phase II trial testing the oligometastasis hypothesis RM Glicksman, U Metser, D Vines, J Valliant, Z Liu, PW Chung, ... European urology 80 (3), 374-382, 2021 | 70 | 2021 |
| Development and validation of a clinical prognostic stage group system for nonmetastatic prostate cancer using disease-specific mortality results from the international staging … RT Dess, K Suresh, MJ Zelefsky, SJ Freedland, BA Mahal, ... JAMA oncology 6 (12), 1912-1920, 2020 | 69 | 2020 |
